New drug cocktail aims to stop liver cancer recurrence in High-Risk patients
NCT ID NCT04639180
First seen Jan 05, 2026 · Last updated Jun 16, 2026 · Updated 22 times
Summary
This phase 3 trial tests whether combining two drugs (camrelizumab and rivoceranib) can prevent liver cancer from returning in patients at high risk of recurrence after surgery or ablation. About 687 participants will receive either the drug combination or standard monitoring. The main goal is to see how long patients stay cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangxi Medical University Affiliated Tumor Hospital
Nanjin, Guangzhou, China
-
Guizhou Cancer Hospital
Guiyang, Guizhou, China
-
Renji Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
-
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.